Scivita Medical Technology Co., Ltd. (“Scivita Medical”) announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures, with contribution from Matrix Partners China, Medtronic, Chengwei Capital and Shanghai Innochip Investment. The successful completion of the Series A funding round reflects the recognition of Scivita Medical in the field of endoscope and the expectation of its future development from the capital market and industrial strategic partners. Scivita
The post Scivita Medical Raises Nearly RMB0.4 Billion in Series A Funding Round and Strives to Build A World-leading Platform for Innovative Products in Endoscope and Related Fields appeared first on Pharma Mirror Magazine.
